Cemsidomide not checked
C4 Therapeutics, Inc. · CFT7455
FollowEvery change as it happens, and a Monday email
Trials
3 active
3 in total · 1 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “dosed orally (PO) once a day (QD) 14 days on/14 days off for each 28-day cycle”In the company’s words, NCT07284758 on ClinicalTrials.gov
- Tested for
- Multiple Myeloma (2 trials), Relapsed/Refractory Multiple Myeloma, Lymphoma, Non-Hodgkin's, Multiple Myeloma (MM)
- Main trialPhase 2
- “This is a Phase 2, open-label, single-arm, multicenter study to assess the antimyeloma activity and further characterize the safety, tolerability, PK, and PD of cemsidomide in combination with dexamethasone in participants with relapsed/refractory multiple myeloma (r/r MM).”In the company’s words, NCT07284758 on ClinicalTrials.gov
- Other names
- CFT7455
Other drugs for Multiple Myeloma
- MezigdomideCelgene · Phase 3
- Anitocabtagene-autoleucelGilead (Kite) · Phase 3
- CM336Keymed Biosciences Co.Ltd · Phase 3
- IBI3003Innovent · Phase 3
- PomalidomideCelgene · Phase 3
- CevostamabRoche · Phase 3
Coming up2
- Dec 2028Phase 1 trial completes · ClinicalTrials.gov
- Mar 2030Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | Mar 2030 | A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma | |
| Phase 1Active, not recruiting | 30 Sep 2026 | Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma | |
| Phase 1Recruiting | Dec 2028 | A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026